Labcorp Holdings marked substantial development in its recent financial performances. The company's
quarterly dividends and strong earnings growth underline revived confidence in its capital allocation strategy.
UBS Group and Truist Financial both have increased their price targets for Labcorp's stocks, signifying renewed investor faith.
Mizuho has also updated its price target. Labcorp's valuation is being reassessed in light of robust earnings and positive guidance. The company displayed successful Q3 earnings, surpassing estimates, leading their stocks to reach a
52-week high. Their
Biopharma Growth initiative has supercharged their financial outlook. The company also announced the acquisition of assets of
BioReference Health's Oncology and related clinical testing services businesses. It is suggested that Labcorp’s Digital Pathology partnership with
Roche is beneficial for shareholders.
Aberdeen Group,
Allspring Global Investments Holdings, and
Equitable Trust Co have raised their positions in Labcorp. Also, noteworthy is Labcorp's
Alzheimer's diagnostic blood test being launched nationwide showcasing growth and innovation. Insights from Q2 earnings reveal strong earnings growth and robust sales. However, a noteworthy point of concern was Labcorp selling $8.7 million in stock.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 08 Jan 2025 08:00:00 GMT to Sat, 18 Oct 2025 14:14:45 GMT -
Rating 9
- Innovation 7
- Information 9
- Rumor -1
